drugset / Trial / NCT00695955

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955

Phase 3 Completed 669 enrolled Takeda
Non-randomizedOpen-labelTreatment

Summary

This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.

Timeline

Start
2007-06
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Background Chlorthalidone Other / unclassified 25 mg
Background Hydrochlorothiazide Unknown 12.5 mg
Background Hydrochlorothiazide Unknown 25 mg